BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22692505)

  • 1. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
    Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
    Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.
    Nayak RC; Chang KH; Singh AK; Kotliar M; Desai M; Wellendorf AM; Wunderlich M; Bartram J; Mizukawa B; Cuadrado M; Dexheimer P; Barski A; Bustelo XR; Nassar NN; Cancelas JA
    Nat Commun; 2022 Jun; 13(1):3056. PubMed ID: 35650206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
    Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
    J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.
    Wang PY; Young F; Chen CY; Stevens BM; Neering SJ; Rossi RM; Bushnell T; Kuzin I; Heinrich D; Bottaro A; Jordan CT
    Blood; 2008 Nov; 112(10):4184-92. PubMed ID: 18755985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
    Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
    Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
    Hegde S; Gasilina A; Wunderlich M; Lin Y; Buchholzer M; Krumbach OHF; Akbarzadeh M; Ahmadian MR; Seibel W; Zheng Y; Perentesis JP; Mizukawa BE; Vinnedge LP; Cancelas JA; Nassar NN
    Leukemia; 2022 Mar; 36(3):637-647. PubMed ID: 34711926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
    Yi SJ; Lee HT; Groffen J; Heisterkamp N
    Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
    Heisterkamp N; Voncken JW; Senadheera D; Gonzalez-Gomez I; Reichert A; Haataja L; Reinikainen A; Pattengale PK; Groffen J
    Blood; 2000 Sep; 96(6):2226-32. PubMed ID: 10979970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Pax5 Exploits Sca1-BCR-ABL
    Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
    Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
    Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
    Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
    Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
    Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
    Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
    J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Yuanxin Y; Yanhong Z; Qin Z; Sishi T; Yang D; Yi Z; Minjin W; Juan Z; Xiaojun L; Lanlan W; Binwu Y
    Leuk Res; 2019 Apr; 79():6-16. PubMed ID: 30784762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
    Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
    Daubon T; Rochelle T; Bourmeyster N; Génot E
    Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.
    Sengupta A; Arnett J; Dunn S; Williams DA; Cancelas JA
    Blood; 2010 Jul; 116(1):81-4. PubMed ID: 20407032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.